Ligand Pharmaceuticals Incorporated Stock News

IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.

Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.

Verus Capital Partners LLC trimmed its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 32.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities & E

Stress test results put the brakes on banking stocks. Healthcare and technology are better sectors for alpha-generating ideas. Top stocks to add to watch lists

Stress test results put the brakes on banking stocks. Healthcare and technology are better sectors for alpha-generating ideas. Top stocks to add to watch lists

- Die Kombination aus Genomik, Transkriptomik und Proteomik wirft Licht auf autoimmune Schilddrüsenerkrankungen, andere Autoimmunerkrankungen und AML

Nuveen Asset Management LLC increased its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 7.9% in the first quarter, according to the company in its most recent Form 13F filing with th

Cyclica, a startup developing an AI-powered platform for drug discovery, has secured $23 million in venture capital financing.

While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.

M&T Bank Corp purchased a new position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commis

LGND vs. RGEN: Which Stock Is the Better Value Option?

Ligand stock had been buoyant prior to last week's market selloff, reaching a high of $124. The company helps biotech and pharmaceutical companies discover and

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Vernalis Research, a Ligand company, has expanded its oncology research collaboration with Servier, an international pharmaceutical co

Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, BidAskClub reports. LGN